IL6 and obesity disorder: In a randomized, double-blind controlled clinical trial involving people with obesity, blockade of IL-6 signaling through monthly infusions of tocilizumab (an IL-6 receptor antagonist) eliminated the aerobic exercise-induced reduction in epicardial and pericardial adipose tissue, as well as the expected increase in left ventricular mass (Christensen et al, 2019).